Published in Leukemia on April 02, 2009
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34
How we treat Richter syndrome. Blood (2014) 1.31
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia (2015) 0.89
Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica (2011) 0.88
Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev (2014) 0.82
The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis. PLoS One (2015) 0.81
Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev (2016) 0.78
The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients. Cancer Manag Res (2015) 0.76
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. Mediterr J Hematol Infect Dis (2016) 0.75
A Systematic Review of Spiritually Based Interventions and Psychoneuroimmunological Outcomes in Breast Cancer Survivorship. Integr Cancer Ther (2016) 0.75
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol (2017) 0.75
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med (1997) 2.73
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood (2001) 2.73
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. Dig Liver Dis (2005) 2.18
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics (1997) 1.68
Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost (2005) 1.66
Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation (1990) 1.63
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). Tissue Antigens (1990) 1.57
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet (1989) 1.57
Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.55
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med (1990) 1.52
Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood (2001) 1.52
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol (2013) 1.51
The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood (1989) 1.51
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia (2006) 1.51
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res (2011) 1.50
Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst (1990) 1.49
Low dose prednisolone administration in routine ICSI patients does not improve pregnancy and implantation rates. Hum Reprod (2002) 1.47
Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis (1997) 1.47
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Molecular pathophysiology of indolent lymphoma. Haematologica (2000) 1.42
p53 mutations are associated with histologic transformation of follicular lymphoma. Blood (1993) 1.40
'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood (1991) 1.40
Nucleolar organizer regions in mucinous tumours of the ovary. Histopathology (1990) 1.40
Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL) Leukemia (1994) 1.39
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica (1999) 1.39
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med (2000) 1.38
Do not forget lupus anticoagulant in the era of antiphospholipid antibodies. Nephron (1997) 1.38
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol (2008) 1.34
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood (1992) 1.33
Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood (1988) 1.33
Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med (1989) 1.32
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.31
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest (1985) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood (1994) 1.28
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol (1999) 1.26
Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer (2010) 1.25
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia (1998) 1.23
Effects of insulin on hemodynamics and metabolism in human forearm. Diabetes (1990) 1.20
Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol (1996) 1.20
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia (1994) 1.16
6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood (1993) 1.16
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood (1998) 1.16
Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol (1998) 1.16
The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia (2012) 1.14
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol (1984) 1.12
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer (2004) 1.11
Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood (1992) 1.11
Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood (2000) 1.11
Ras oncogene mutation in multiple myeloma. J Exp Med (1989) 1.11
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 1.10
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer (1997) 1.10
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia (2005) 1.10
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia (2011) 1.09
Management of poor responders in IVF. Reprod Biomed Online (2005) 1.09
Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. Leukemia (1999) 1.08
Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. AIDS (1996) 1.08
Relationship between meiotic spindle location with regard to the polar body position and oocyte developmental potential after ICSI. Hum Reprod (2003) 1.08
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia (2012) 1.07
Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells. Proc Natl Acad Sci U S A (1981) 1.06
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia (2010) 1.06
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol (2013) 1.05
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood (1993) 1.05
Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS (2000) 1.04
Primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Leuk Lymphoma (2000) 1.04